vs
亚玛芬体育（AS）与West Pharmaceutical Services（WST）财务数据对比。点击上方公司名可切换其他公司
亚玛芬体育的季度营收约是West Pharmaceutical Services的1.3倍（$1.1B vs $805.0M），West Pharmaceutical Services净利率更高（16.4% vs 1.8%，领先14.6%），West Pharmaceutical Services自由现金流更多（$175.0M vs $92.2M）
亚玛芬体育是芬兰跨国运动装备企业，总部位于赫尔辛基，成立于1950年。早年为涉足烟草贸易、航运、出版等领域的多元化工业集团，后逐步转型专注于体育用品的生产与营销，现有员工超9700人，2018年起成为中国安踏体育旗下子公司。
美国West Pharmaceutical Services是注射用药品包装及给药系统的设计和制造商，1923年成立，总部位于宾夕法尼亚州埃克斯顿。成立初期主营注射类药物包装用橡胶组件，曾为青霉素和胰岛素生产商提供符合无菌要求的配套产品。
AS vs WST — 直观对比
营收规模更大
AS
是对方的1.3倍
$805.0M
净利率更高
WST
高出14.6%
1.8%
自由现金流更多
WST
多$82.8M
$92.2M
损益表 — Q1 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $805.0M |
| 净利润 | $19.0M | $132.1M |
| 毛利率 | 52.8% | 37.8% |
| 营业利润率 | 12.4% | 19.5% |
| 净利率 | 1.8% | 16.4% |
| 营收同比 | — | 7.5% |
| 净利润同比 | — | 1.5% |
| 每股收益（稀释后） | $0.05 | $1.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASWST
| Q4 25 | — | $805.0M | ||
| Q3 25 | — | $804.6M | ||
| Q2 25 | — | $766.5M | ||
| Q1 25 | — | $698.0M | ||
| Q4 24 | — | $748.8M | ||
| Q3 24 | — | $746.9M | ||
| Q2 24 | — | $702.1M | ||
| Q1 24 | $1.1B | $695.4M |
净利润ASWST
| Q4 25 | — | $132.1M | ||
| Q3 25 | — | $140.0M | ||
| Q2 25 | — | $131.8M | ||
| Q1 25 | — | $89.8M | ||
| Q4 24 | — | $130.1M | ||
| Q3 24 | — | $136.0M | ||
| Q2 24 | — | $111.3M | ||
| Q1 24 | $19.0M | $115.3M |
毛利率ASWST
| Q4 25 | — | 37.8% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 35.7% | ||
| Q1 25 | — | 33.2% | ||
| Q4 24 | — | 36.5% | ||
| Q3 24 | — | 35.4% | ||
| Q2 24 | — | 32.8% | ||
| Q1 24 | 52.8% | 33.1% |
营业利润率ASWST
| Q4 25 | — | 19.5% | ||
| Q3 25 | — | 20.8% | ||
| Q2 25 | — | 20.1% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | — | 21.3% | ||
| Q3 24 | — | 21.6% | ||
| Q2 24 | — | 18.0% | ||
| Q1 24 | 12.4% | 17.7% |
净利率ASWST
| Q4 25 | — | 16.4% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | — | 17.2% | ||
| Q1 25 | — | 12.9% | ||
| Q4 24 | — | 17.4% | ||
| Q3 24 | — | 18.2% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | 1.8% | 16.6% |
每股收益（稀释后）ASWST
| Q4 25 | — | $1.82 | ||
| Q3 25 | — | $1.92 | ||
| Q2 25 | — | $1.82 | ||
| Q1 25 | — | $1.23 | ||
| Q4 24 | — | $1.78 | ||
| Q3 24 | — | $1.85 | ||
| Q2 24 | — | $1.51 | ||
| Q1 24 | $0.05 | $1.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $791.3M |
| 总债务越低越好 | — | $202.8M |
| 股东权益账面价值 | — | $3.2B |
| 总资产 | — | $4.3B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资ASWST
| Q4 25 | — | $791.3M | ||
| Q3 25 | — | $628.5M | ||
| Q2 25 | — | $509.7M | ||
| Q1 25 | — | $404.2M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $490.9M | ||
| Q2 24 | — | $446.2M | ||
| Q1 24 | — | $601.8M |
总债务ASWST
| Q4 25 | — | $202.8M | ||
| Q3 25 | — | $202.7M | ||
| Q2 25 | — | $202.6M | ||
| Q1 25 | — | $202.6M | ||
| Q4 24 | — | $202.6M | ||
| Q3 24 | — | $202.6M | ||
| Q2 24 | — | $205.8M | ||
| Q1 24 | — | $206.2M |
股东权益ASWST
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.7B |
总资产ASWST
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | — | $4.0B | ||
| Q1 25 | — | $3.6B | ||
| Q4 24 | — | $3.6B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | — | $3.5B | ||
| Q1 24 | — | $3.6B |
负债/权益比ASWST
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.3M | $251.1M |
| 自由现金流经营现金流 - 资本支出 | $92.2M | $175.0M |
| 自由现金流率自由现金流/营收 | 8.8% | 21.7% |
| 资本支出强度资本支出/营收 | 2.1% | 9.5% |
| 现金转化率经营现金流/净利润 | 6.02× | 1.90× |
| 过去12个月自由现金流最近4个季度 | — | $468.9M |
8季度趋势，按日历期对齐
经营现金流ASWST
| Q4 25 | — | $251.1M | ||
| Q3 25 | — | $197.2M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $129.4M | ||
| Q4 24 | — | $190.1M | ||
| Q3 24 | — | $180.1M | ||
| Q2 24 | — | $165.0M | ||
| Q1 24 | $114.3M | $118.2M |
自由现金流ASWST
| Q4 25 | — | $175.0M | ||
| Q3 25 | — | $133.9M | ||
| Q2 25 | — | $101.9M | ||
| Q1 25 | — | $58.1M | ||
| Q4 24 | — | $85.2M | ||
| Q3 24 | — | $98.8M | ||
| Q2 24 | — | $64.8M | ||
| Q1 24 | $92.2M | $27.6M |
自由现金流率ASWST
| Q4 25 | — | 21.7% | ||
| Q3 25 | — | 16.6% | ||
| Q2 25 | — | 13.3% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 9.2% | ||
| Q1 24 | 8.8% | 4.0% |
资本支出强度ASWST
| Q4 25 | — | 9.5% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 9.8% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | — | 14.0% | ||
| Q3 24 | — | 10.9% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | 2.1% | 13.0% |
现金转化率ASWST
| Q4 25 | — | 1.90× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | — | 1.34× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.48× | ||
| Q1 24 | 6.02× | 1.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AS
| Americas2 | $409.6M | 39% |
| EMEA1 | $356.9M | 34% |
| Greater China3 | $205.6M | 20% |
| Asia Pacific4 | $78.2M | 7% |
WST
| Proprietary Products | $661.8M | 82% |
| Contract Manufactured Products | $143.2M | 18% |
| Affiliated Entity | $3.3M | 0% |
